MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ
5.18
+0.03
+0.58%
After Hours: 5.14 -0.04 -0.77% 18:51 12/31 EST
OPEN
5.17
PREV CLOSE
5.15
HIGH
5.26
LOW
5.11
VOLUME
554.17K
TURNOVER
--
52 WEEK HIGH
7.20
52 WEEK LOW
1.180
MARKET CAP
311.64M
P/E (TTM)
-7.1775
1D
5D
1M
3M
1Y
5Y
1D
Aldeyra Therapeutics Announces Chief Development Officer Resignation
TipRanks · 12/31/2025 22:29
Aldeyra Therapeutics Grants $88,000 Transition Bonus to Departing Chief Development Officer
Reuters · 12/31/2025 22:07
Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst
Seeking Alpha · 12/30/2025 23:26
Weekly Report: what happened at ALDX last week (1222-1226)?
Weekly Report · 12/29/2025 10:21
Weekly Report: what happened at ALDX last week (1215-1219)?
Weekly Report · 12/22/2025 10:21
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
TipRanks · 12/17/2025 11:25
BUZZ-U.S. STOCKS ON THE MOVE-Sunrun, PayPal, Caris
Reuters · 12/16/2025 18:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/16/2025 17:05
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.